Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 9, 2012, Pages 1520-1530

  Flowers, Christopher R ^a,b   Fedewa, Stacey A ^d   Chen, Amy Y ^b,d   Nastoupil, Loretta J ^a,b   Lipscomb, Joseph ^b,c   Brawley, Otis W ^b,d   Ward, Elizabeth M ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOLOGIC AGENT; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CLINICAL PRACTICE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE DISPARITY; HEALTH CARE FACILITY; HEALTH INSURANCE; HUMAN; IMMUNOCHEMOTHERAPY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL EDUCATION; MEDICAL RESEARCH; PRIORITY JOURNAL; RACE; RISK FACTOR; SOCIAL STATUS; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEALTHCARE DISPARITIES; HUMANS; IMMUNOTHERAPY; INSURANCE, HEALTH; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; SEER PROGRAM; SOCIAL CLASS;

EID: 84866155379     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0466     Document Type: Article

References (44)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin 2010;60:393-408.
3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
4. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484-93.
5. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998;92:1927-32.
6. Coiffier B, Lepage E, Herbrecht R, Tilly H, Solal-Celigny P, Munck JN, et al. Mabthera (Rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large-B-cell lymphoma (DLCL): Interim results of a randomized GELA trial. Blood 2000;96:223A Abstr #950.
7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
8. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-5.
9. Pfreundschuh MG, Trumper L, Ma D, Österborg A, Pettengell R, Trneny M, et al. Randomized intergroup trial of first line treatment for patients < = 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab-early stopping after the first interim analysis. Proc Amer Soc Clin Oncol 2004:Abstr #6500.
10. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7.
11. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004:221-36.
12. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6.
13. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, et al. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's lymphoma v.1.2012. J Natl Compr Canc Netw 2011;9:484-560.
14. ICD-O International Classification of Diseases for Oncology. Geneva: World Health Organization; 1976.
15. Deddens JA, Petersen MR. Approaches for estimating prevalence ratios. Occup Environ Med 2008;65:481, 501-6.
16. Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 2010 Dec 22. [Epub ahead of print].
17. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002;40:IV-104-17.
18. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
19. Pfreundschuh M, Kloess M, Zeynalova S, Lengfelder E, Franke A, Reiser M, et al. Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). Blood 2006;108:205.
20. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncology 2008;9:105-16.
21. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33.
22. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-97.
23. Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005). J Natl Cancer Inst 2008;100:462-74.
24. Glover R, Shenoy P, Kharod GA, Schaefer A, Bumpers K, Berry JTM, et al. Patterns of social support among lymphoma patients considering stem cell transplantation. Soc Work Health Care 2011;50:815-27.
25. Flowers CR, Melmon KL. Clinical investigators as critical determinants in pharmaceutical innovation. Nat Med 1997;3:136-43.
26. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-10.
27. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
28. Pappas DP, Garbus JE, Feuerman M, Reed WP. Improving uniformity of care for colorectal cancers through National Quality Forum quality indicators at a Commission on Cancer-accredited community based teaching hospital. Surg Oncol Clin N Am 2011;20:587-96, x.
29. The A, Li Y, Reddy V, Davis R, Baird M, Foran J. A comparative study of diffuse large B-cell lymphoma (DLBCL) between African Americans and Caucasians: single-center experience at the University of Alabama at Birmingham (UAB). Blood (ASH Annual Meeting Abstracts) 2007;110:4430.
30. Vance KT, Kilgore ML, Yun H, Gary LC, Foran JM. Race and non-Hodgkin's lymphoma: adverse impact of race and treatment delays on survival. A SEER-Medicare Population Study (1995-2003). Blood (ASH Annual Meeting Abstracts) 2007;110:3578.
31. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer 2008;113:3231-41.
32. Flowers CR, Glover R, Lonial S, Brawley OW. Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer 2007;31:182-201.
33. Malik N, Shenoy PJ, Bumpers K, Sinha R, Flowers CR. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Blood (ASH Annual Meeting Abstracts) 2009;114:Abstr #898.
34. Powe NR, Cooper LA. Diversifying the racial and ethnic composition of the physician workforce. Ann Intern Med 2004;141:223-4.
35. Lavizzo-Mourey R, Lumpkin JR. From unequal treatment to quality care. Ann Intern Med 2004;141:221.
36. Groman R, Ginsburg J. Racial and ethnic disparities in health care: a position paper of the American College of Physicians. Ann Intern Med 2004;141:226-32.
37. Kaplan SH, Greenfield S. The Patient's role in reducing disparities. Ann Intern Med 2004;141:222-3.
38. Hayes N, Rollins R, Weinberg A, Brawley O, Baquet C, Kaur JS, et al. Cancer-related disparities: weathering the perfect storm through comprehensive cancer control approaches. Cancer Causes Control 2005;16 Suppl 1:41-50.
39. Reddy S, Shapiro M, Morton R Jr., Brawley OW. Prostate cancer in black and white Americans. Cancer Metastasis Rev 2003;22:83-6.
40. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA 2002;287:2106-13.
41. Brawley OW. Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment. J Clin Oncol 2006;24:332-3.
42. Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, et al. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk 2011;11:257-60.
43. Flowers CR, Shenoy PJ, Borate U, Bumpers K, Douglas-Holland T, King N, et al. Examining racial differences in diffuse large B-cell lymphoma presentation and Survival. Leuk Lymphoma. 2012 Jul 16. [Epub ahead of print].
44. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.